264 related articles for article (PubMed ID: 32492164)
1. Regional Disparities in Qualified Health Plans' Prior Authorization Requirements for HIV Pre-exposure Prophylaxis in the United States.
McManus KA; Powers S; Killelea A; Tello-Trillo S; Rogawski McQuade E
JAMA Netw Open; 2020 Jun; 3(6):e207445. PubMed ID: 32492164
[TBL] [Abstract][Full Text] [Related]
2. Geographic Variation in Qualified Health Plan Coverage and Prior Authorization Requirements for HIV Preexposure Prophylaxis.
McManus KA; Fuller B; Killelea A; Strumpf A; Powers SD; Rogawski McQuade ET
JAMA Netw Open; 2023 Nov; 6(11):e2342781. PubMed ID: 37948076
[TBL] [Abstract][Full Text] [Related]
3. Implementation Strategies to Increase PrEP Uptake in the South.
Sullivan PS; Mena L; Elopre L; Siegler AJ
Curr HIV/AIDS Rep; 2019 Aug; 16(4):259-269. PubMed ID: 31177363
[TBL] [Abstract][Full Text] [Related]
4. Evidence From a Multistate Cohort: Enrollment in Affordable Care Act Qualified Health Plans' Association With Viral Suppression.
McManus KA; Christensen B; Nagraj VP; Furl R; Yerkes L; Swindells S; Weissman S; Rhodes A; Targonski P; Rogawski McQuade E; Dillingham R
Clin Infect Dis; 2020 Dec; 71(10):2572-2580. PubMed ID: 31734691
[TBL] [Abstract][Full Text] [Related]
5. Trends in the use of oral emtricitabine/tenofovir disoproxil fumarate for pre-exposure prophylaxis against HIV infection, United States, 2012-2017.
Sullivan PS; Giler RM; Mouhanna F; Pembleton ES; Guest JL; Jones J; Castel AD; Yeung H; Kramer M; McCallister S; Siegler AJ
Ann Epidemiol; 2018 Dec; 28(12):833-840. PubMed ID: 30037634
[TBL] [Abstract][Full Text] [Related]
6. The prevalence of pre-exposure prophylaxis use and the pre-exposure prophylaxis-to-need ratio in the fourth quarter of 2017, United States.
Siegler AJ; Mouhanna F; Giler RM; Weiss K; Pembleton E; Guest J; Jones J; Castel A; Yeung H; Kramer M; McCallister S; Sullivan PS
Ann Epidemiol; 2018 Dec; 28(12):841-849. PubMed ID: 29983236
[TBL] [Abstract][Full Text] [Related]
7. Preexposure Prophylaxis for the Prevention of HIV Infection: Evidence Report and Systematic Review for the US Preventive Services Task Force.
Chou R; Evans C; Hoverman A; Sun C; Dana T; Bougatsos C; Grusing S; Korthuis PT
JAMA; 2019 Jun; 321(22):2214-2230. PubMed ID: 31184746
[TBL] [Abstract][Full Text] [Related]
8. Access to a novel first-line single-tablet HIV antiretroviral regimen in Affordable Care Act Marketplace plans, 2018-2020.
Khazanchi R; Powers S; Killelea A; Strumpf A; Horn T; Hamp A; McManus KA
J Pharm Policy Pract; 2023 Apr; 16(1):57. PubMed ID: 37081570
[TBL] [Abstract][Full Text] [Related]
9. Preexposure Prophylaxis for the Prevention of HIV Infection: US Preventive Services Task Force Recommendation Statement.
; Owens DK; Davidson KW; Krist AH; Barry MJ; Cabana M; Caughey AB; Curry SJ; Doubeni CA; Epling JW; Kubik M; Landefeld CS; Mangione CM; Pbert L; Silverstein M; Simon MA; Tseng CW; Wong JB
JAMA; 2019 Jun; 321(22):2203-2213. PubMed ID: 31184747
[TBL] [Abstract][Full Text] [Related]
10. Small-area spatial-temporal changes in pre-exposure prophylaxis (PrEP) use in the general population and among men who have sex with men in the United States between 2012 and 2018.
Mouhanna F; Castel AD; Sullivan PS; Kuo I; Hoffman HJ; Siegler AJ; Jones JS; Mera Giler R; McGuinness P; Kramer MR
Ann Epidemiol; 2020 Sep; 49():1-7. PubMed ID: 32951802
[TBL] [Abstract][Full Text] [Related]
11. Failure of pre-exposure prophylaxis with daily tenofovir/emtricitabine and the scenario of delayed HIV seroconversion.
Lee SS; Anderson PL; Kwan TH; Lui GCY; Chan DPC; Wong NS; Lee KCK; Lam TTN
Int J Infect Dis; 2020 May; 94():41-43. PubMed ID: 32173577
[TBL] [Abstract][Full Text] [Related]
12. On-demand pre-exposure prophylaxis with tenofovir disoproxil fumarate plus emtricitabine among men who have sex with men with less frequent sexual intercourse: a post-hoc analysis of the ANRS IPERGAY trial.
Antoni G; Tremblay C; Delaugerre C; Charreau I; Cua E; Rojas Castro D; Raffi F; Chas J; Huleux T; Spire B; Capitant C; Cotte L; Meyer L; Molina JM;
Lancet HIV; 2020 Feb; 7(2):e113-e120. PubMed ID: 31784343
[TBL] [Abstract][Full Text] [Related]
13. Association of HIV Preexposure Prophylaxis With Incidence of Sexually Transmitted Infections Among Individuals at High Risk of HIV Infection.
Traeger MW; Cornelisse VJ; Asselin J; Price B; Roth NJ; Willcox J; Tee BK; Fairley CK; Chang CC; Armishaw J; Vujovic O; Penn M; Cundill P; Forgan-Smith G; Gall J; Pickett C; Lal L; Mak A; Spelman TD; Nguyen L; Murphy DA; Ryan KE; El-Hayek C; West M; Ruth S; Batrouney C; Lockwood JT; Hoy JF; Hellard ME; Stoové MA; Wright EJ;
JAMA; 2019 Apr; 321(14):1380-1390. PubMed ID: 30964528
[TBL] [Abstract][Full Text] [Related]
14. Review of Real-World Implementation Data on Emtricitabine-Tenofovir Disoproxil Fumarate as HIV Pre-exposure Prophylaxis in the United States.
Adams JL; Shelley K; Nicol MR
Pharmacotherapy; 2019 Apr; 39(4):486-500. PubMed ID: 30815960
[TBL] [Abstract][Full Text] [Related]
15. Uptake of Oral HIV Pre-Exposure Prophylaxis (PrEP) and Associated Factors among Female Sex Workers in Tanga, Tanzania.
Martin VO; Tesha NA; Sunguya BF
Viruses; 2023 Oct; 15(10):. PubMed ID: 37896903
[TBL] [Abstract][Full Text] [Related]
16. Population-level effectiveness of rapid, targeted, high-coverage roll-out of HIV pre-exposure prophylaxis in men who have sex with men: the EPIC-NSW prospective cohort study.
Grulich AE; Guy R; Amin J; Jin F; Selvey C; Holden J; Schmidt HA; Zablotska I; Price K; Whittaker B; Chant K; Cooper C; McGill S; Telfer B; Yeung B; Levitt G; Ogilvie EE; Dharan NJ; Hammoud MA; Vaccher S; Watchirs-Smith L; McNulty A; Smith DJ; Allen DM; Baker D; Bloch M; Bopage RI; Brown K; Carr A; Carmody CJ; Collins KL; Finlayson R; Foster R; Jackson EY; Lewis DA; Lusk J; O'Connor CC; Ryder N; Vlahakis E; Read P; Cooper DA;
Lancet HIV; 2018 Nov; 5(11):e629-e637. PubMed ID: 30343026
[TBL] [Abstract][Full Text] [Related]
17. HIV pre-exposure prophylaxis in transgender women: a subgroup analysis of the iPrEx trial.
Deutsch MB; Glidden DV; Sevelius J; Keatley J; McMahan V; Guanira J; Kallas EG; Chariyalertsak S; Grant RM;
Lancet HIV; 2015 Dec; 2(12):e512-9. PubMed ID: 26614965
[TBL] [Abstract][Full Text] [Related]
18. Protocol for an open-label, single-arm trial of HIV pre-exposure prophylaxis (PrEP) among people at high risk of HIV infection: the NSW Demonstration Project PRELUDE.
Vaccher S; Grulich A; McAllister J; Templeton DJ; Bloch M; McNulty A; Holden J; Poynten IM; Prestage G; Zablotska I;
BMJ Open; 2016 Jun; 6(6):e012179. PubMed ID: 27324719
[TBL] [Abstract][Full Text] [Related]
19. Pre-exposure prophylaxis to prevent HIV infection: current status, future opportunities and challenges.
Krakower DS; Mayer KH
Drugs; 2015 Feb; 75(3):243-51. PubMed ID: 25673022
[TBL] [Abstract][Full Text] [Related]
20. Anti-retroviral Therapy Based HIV Prevention Among a Sample of Men Who Have Sex with Men in Cape Town, South Africa: Use of Post-exposure Prophylaxis and Knowledge on Pre-exposure Prophylaxis.
Hugo JM; Stall RD; Rebe K; Egan JE; De Swardt G; Struthers H; McIntyre JA
AIDS Behav; 2016 Dec; 20(Suppl 3):357-364. PubMed ID: 27631366
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
